Alimera Sciences plans to raise $100m in a public offering of securities including common stock, preferred stock, debt securities, warrants and units.
The biopharmaceutical company plans to use the funds for general corporate purposes.
Go deeper with GlobalData
ThromboGenics NV plans to raise €10m ($11.82m) through a private placement of shares.
The placement was subscribed to by Novartis.
Biopharmaceutical company AbbVie has signed an agreement with biotechnology company Alector to develop medicines targeting Alzheimer’s disease and other neurodegenerative disorders.
Alector will carry out exploratory research, while AbbVie will have the option to conduct development and commercialisation activities under the agreement.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe deal will help the two companies to develop innovative therapies for Alzheimer’s disease. Both companies involved are based in the US.
South Korean pharmaceutical company Choa Pharmaceutical has raised KRW12bn ($10.59m) through a public offering of private convertible bonds.
The bonds are due on 24 April 2022.
